Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Cranbury Pharmaceuticals operates as a wholly owned subsidiary of Tris Pharma Inc., an innovative biopharmaceutical company focused on pioneering differentiated approaches to improve therapeutic benefits and optimize patient outcomes. Tris Pharma specializes in addressing conditions such as attention-deficit/hyperactivity disorder (ADHD), pain management, addiction, and diseases affecting the central nervous system (CNS). By l...
Cranbury Pharmaceuticals operates as a wholly owned subsidiary of Tris Pharma Inc., an innovative biopharmaceutical company focused on pioneering differentiated approaches to improve therapeutic benefits and optimize patient outcomes. Tris Pharma specializes in addressing conditions such as attention-deficit/hyperactivity disorder (ADHD), pain management, addiction, and diseases affecting the central nervous system (CNS). By leveraging innovative research and development, Tris Pharma and its subsidiary Cranbury Pharmaceuticals aim to advance treatment options and provide effective solutions for patients in need.

List your booth number for exhibitions, ask us